| Document |
Document Title |
|
WO/2001/055152A1 |
This invention provides novel benzoethers of formulae (I, II). These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Thus, this invention also provides pharmace...
|
|
WO/2001/051479A2 |
The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X = O, (CH¿2?)¿m?, S, SO, SO¿2?, NH, NR¿8? or ...
|
|
WO/2001/049674A2 |
A method for synthesizing Salacinol, its stereoisomers, and non-naturally occurring selenium and nitrogen analogues thereof having formula (I). The compounds are potentially useful as glycosidase inhibitors. The synthetic schemes compris...
|
|
WO/2001/040214A1 |
Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.
|
|
WO/2001/011968A2 |
Heterocyclic spiro compounds of formula (I) or salts thereof, wherein the symbols have the meaning given in the description, are useful for combatting animal pest.
|
|
WO/2001/007453A1 |
Anticonvulsant compounds of general formula (I) where X, R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, and R¿6? are as herein defined; are useful in treating acute ischemia-induced neurodegeneration, such as occurs during and after stroke, head tr...
|
|
WO/2001/005790A1 |
The present invention relates to certain spirooxindole derivatives of formula (I), and pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are particulary effective in the treatment of chronic pain.
|
|
WO/2001/004124A1 |
This invention provides novel oxathiepino[6,5-b]dihydropyridines. These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Thus, this invention also provides pharm...
|
|
WO/2000/056918A1 |
A method for screening a cysteine protease inhibitor potentiating the cysteine protease inhibitory activity in the presence of polyvalent metal ions which comprises treating cysteine protease with a test compound in the presence of polyv...
|
|
WO/2000/041691A1 |
Novel dry skin remedies useful for the treatment of dry skin, containing as the active ingredient spiro[oxathiolane-quinuclidine] derivatives represented by general formula (I) or acid addition salts thereof, desirably cis-2-methylspiro[...
|
|
WO1999051238A9 |
The present invention is directed to several newly prepared semi-synthetic ecteinascidin (Et) species, designated herein as Et 757, Boc-Et 729, Iso-Et 743, Et 875, and Et 1560. The physical properties of these compounds, their preparatio...
|
|
WO/1999/058125A1 |
The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as 'ETM' followed by a numeric value which represents th...
|
|
WO/1999/054319A1 |
The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
|
|
WO/1999/054318A1 |
The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
|
|
WO/1999/012929A2 |
Porphyrazine compounds having moieties substituted at the eight peripheral $g(b)-pyrrole positions are disclosed. The porphyrazine compounds have general structural formula (V), wherein M is H¿2? or a metal capable of complexing with th...
|
|
WO/1998/058246A2 |
The invention provides compounds and intermediaries in their production useful as cation sensors and/or extractors, the compounds comprising a redox active group and a cation sensing group and/or a thiol terminating group. The compounds ...
|
|
WO/1997/042185A1 |
Compounds of formula (I), and their N-oxides and agriculturally suitable salts, are disclosed which are useful for controlling undesired vegetation. In said formula (I) Q is (Q-1), (Q-2) or (Q-3); and A, R1-R7, and q are as defined in th...
|
|
WO/1997/030992A1 |
This invention relates to compounds that inhibit farnesyl-protein transferase and ras protein farnesylation, thereby making them useful as anti-cancer agents. The compounds are also useful in the treatment of diseases, other than cancer,...
|
|
WO/1997/023462A1 |
The invention provides compounds of formula (I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents o...
|
|
WO/1997/019086A1 |
The invention relates to epothilone derivatives and the use thereof.
|
|
WO/1997/016729A1 |
Combinatorial libraries are disclosed which are represented by Formula (I), wherein S is a solid support; T'-L- is an identifier residue; and -L'-II' is a ligand/linker residue. These libraries contain dihydrobenzopyrans of Formula (II) ...
|
|
WO/1996/039367A1 |
The invention provides novel persistent free radicals useful in Overhauser MRI being triarylmethyl radicals having as at least one aryl group a group of formula (1) or (2), wherein each X which may be the same or different is an oxygen o...
|
|
WO/1996/028449A1 |
Porphyrazine compounds having moieties substituted at the eight peripheral 'beta'-pyrrole positions are disclosed. The porphyrazine compounds have general structural formula (V), wherein M is H2 or a metal capable of complexing with the ...
|
|
WO/1996/022288A1 |
This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with ...
|
|
WO/1996/014326A1 |
A compound represented by formula (I), wherein Z is a tetrahydro-pyrano group selected from (a) and (b), having antifungal activity, processes for their preparation and their use in medicine.
|
|
WO/1995/030642A1 |
Combinatorial libraries are disclosed which are represented by the Formula (I): (T'-L)q- S -C(O)-L'-II' wherein S is a solid support; T'-L- is an identifier residue; and -L'-II' is a ligand/linker residue. These libraries contain dihydro...
|
|
WO/1995/017406A1 |
A compound of general formula (I) is disclosed as a potent anticonvulsant drug. Pharmaceutical compositions and methods of treatment are also disclosed.
|
|
WO/1995/015327A1 |
Compounds of formula (I) where B, R1, R2, n and A have the meanings given in the description, and their preparation are described. The novel compounds are suitable for the control of diseases.
|
|
WO/1995/004531A1 |
Fibrinogen receptor antagonists having formula (I) for example formula (a).
|
|
WO/1995/003303A2 |
The invention relates to spiro compounds having central and peripheral nervous system activity, for example muscarinic agonist activity, having formulae (I, II, III, IV, V, VI, VII, VIII and IX) and their pharmaceutically acceptable salt...
|
|
WO/1994/029301A1 |
The present invention relates to a process for producing predominantly pure cis nucleoside analogues using a novel bicyclic intermediate of formula (III), wherein X is S, or O; Y is S, CH2, O or CH(R); wherein R is azido or halogen; and ...
|
|
WO/1994/027594A2 |
There is disclosed stable copper(I) complexes and methods relating thereto. The stable copper(I) complexes comprise a copper(I) ion complexed by a multi-dentate ligand which favors the +1 oxidation state for copper. Methods of this inven...
|
|
WO/1994/012478A1 |
This invention relates to compounds of formula (I) which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.
|
|
WO/1994/009793A1 |
The invention is a method for the treatment of humans infected with HBV that includes administering an HBV treatment amount of an enatiomerically pure beta-D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH2 or H, and...
|
|
WO/1994/004154A1 |
A method and composition for the treatment of humans infected with HIV that includes the administration of an HIV treatment amount of an enantiomerically pure beta-D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH2, ...
|
|
WO/1993/009122A1 |
Tetrahydrobenzothienopyridines of formula (I), processes for their preparation and their use in the treatment and/or prophylaxis of CNS disorders (I).
|
|
WO/1993/007128A1 |
This invention relates to substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors, to pharmaceutical compositions comprising such compounds, and to methods of using these compounds for treating viral...
|
|
WO/1993/002710A2 |
The present invention provides the use of a persistent aryloxy or arylthio free radicals, other than perhalo radicals, for the manufacture of a contrast medium for use in magnetic resonance imaging. Also provided are magnetic resonance i...
|
|
WO/1993/002711A1 |
The present invention provides the use of a persistent $g(p)-system free radical for the manufacture of a contrast medium for use in magnetic resonance imaging, wherein the electron delocalising $g(p)-system of said radical comprises at ...
|
|
WO/1993/002084A1 |
A process for the production of ambergris-type labdane spiroketals of general formulae (I) and (II), where R represents oxygen or sulphur, useful in the perfumery industry, the said process being characterized by the intramolecular cycli...
|
|
WO/1992/010496A1 |
An asymmetric process for the preparation of enantiomerically pure $g(b)-L-(-)-1,3-oxathiolane-nucleosides that includes the initial preparation of the key chiral intermediates (2R,5R) and (2R,5S)-5-(O-protected)-2-(protected-oxymethyl)-...
|
|
WO/1992/010479A1 |
Bicyclic and polycyclic amidic derivatives of glumatic, aspartic and 2-amino adipic acids having activities antagonistic to gastrin, of general formula (I) in which r is between 1 and 3 and R¿1? is selected from mono- and disubstituted ...
|
|
WO/1992/010497A1 |
An asymmetric process for the preparation of enantiomerically pure beta-D-(-)-dioxolane-nucleosides. The enantiomerically pure dioxolane nucleosides are active HIV agents, that are significantly more effective than the prior prepared rac...
|
|
WO/1992/005146A1 |
This invention is directed to a stereoselective process and useful intermediates for the preparation of substantially optically pure acid sensitive compounds including certain dibenzofuran-carboxamides and dibenzofurancarboxamide acids.
|
|
WO/1991/013872A1 |
A therapeutically useful compound of formula (I) or pharmaceutically acceptable salts thereof where A and B are oxygen, sulfur or CH2, X is an amine moiety as defined herein and R1 and R2 are as defined herein having 5HT1A neuronal activ...
|
|
WO/1991/012024A1 |
The invention relates to the use of carbon stable free radicals as image enhancements agents in Overhauser MRI.
|
|
WO/1991/004256A1 |
Process for alkylatine protected spectinomycin enone derivatives in the gamma position in order to produce intermediates useful in the synthesis of 6'alkylspectinomycins. The intermediate have formula (III) which comprises reacting a com...
|
|
WO/1991/002741A1 |
The invention provides a novel class of versatile intermediates, i.e. 1,4 cyclic sulfates of sugar alcohols having protected hydroxy groups, such as 1,4 cyclic sulfates of D-mannitol having protected 2-, 3-, 5- and 6-hydroxy groups and D...
|
|
WO/1988/005047A1 |
Novel carbamoyloxylabdanes, intermediates and processes for the preparation thereof, and methods for reducing intraocular pressure and treating cardiac failure utilizing compounds and compositions thereof.
|
|
JP2024031926A |
The present invention provides a resist composition and the like that can produce a resist pattern having good line edge roughness. The present invention provides an acid generator, etc., and a resist composition using a salt represented...
|
